Stephen Opat
Impact in
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research
- Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 104
- Chronic Lymphocytic Leukemia Research 96
-
- Lymphoma Diagnosis and Treatment 111
- Co-authors
- Constantine Si Lun Tam (41 shared papers)John Francis Seymour (17 shared papers)Jake Shortt (32 shared papers)Judith Trotman (24 shared papers)Marek Trněný (3 shared papers)Elizabeth H. Phillips (2 shared papers)Günter Fingerle‐Rowson (2 shared papers)Rudolf Schlag (2 shared papers)
- Journals
- Blood (41 papers)Hematological Oncology (20 papers)Blood Advances (18 papers)HemaSphere (10 papers)British Journal of Haematology (8 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Stephen Opat
189 papers receiving 8.4k citations
Stephen Opat's Hit Papers
Peers
Comparison fields: 5 of 102
- Genetics 4.8k
- Pathology and Forensic Medicine 4.7k
- Hematology 1.4k
- Immunology 1.9k
- Oncology 2.1k
Countries citing papers authored by Stephen Opat
This map shows the geographic impact of Stephen Opat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Opat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Opat more than expected).
Fields of papers citing papers by Stephen Opat
This network shows the impact of papers produced by Stephen Opat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Opat. The network helps show where Stephen Opat may publish in the future.
Co-authors
The 25 scholars most cited alongside Stephen Opat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 202 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions Hit paper breakdown → | 2014 | 1221 |
| 2 | Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions Hit paper breakdown → | 2019 | 653 |
| 3 | Obinutuzumab for the First-Line Treatment of Follicular Lymphoma Hit paper breakdown → | 2017 | 597 |
| 4 | Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Hit paper breakdown → | 2018 | 554 |
| 5 | Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial Hit paper breakdown → | 2020 | 460 |
| 6 | A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study Hit paper breakdown → | 2020 | 365 |
| 7 | 2019 | 301 | |
| 8 | 2011 | 278 | |
| 9 | Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial Hit paper breakdown → | 2020 | 265 |
| 10 | Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial Hit paper breakdown → | 2022 | 211 |
| 11 | 2021 | 180 | |
| 12 | Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort Hit paper breakdown → | 2022 | 176 |
| 13 | 2021 | 145 | |
| 14 | 2007 | 111 | |
| 15 | 2014 | 111 | |
| 16 | 2013 | 109 | |
| 17 | 2015 | 105 | |
| 18 | 2018 | 105 | |
| 19 | 2017 | 103 | |
| 20 | 2018 | 102 |
About Stephen Opat
Stephen Opat is a scholar working on Genetics, Pathology and Forensic Medicine, Hematology, Oncology and Immunology, having authored 202 papers that have together received 8.5k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (111 papers), Chronic Lymphocytic Leukemia Research (96 papers), Immunodeficiency and Autoimmune Disorders (23 papers), CNS Lymphoma Diagnosis and Treatment (18 papers), Viral-associated cancers and disorders (18 papers), Chronic Myeloid Leukemia Treatments (15 papers), CAR-T cell therapy research (12 papers) and Gastrointestinal Tumor Research and Treatment (8 papers). The work is most often cited by research in Genetics (4.8k citations), Pathology and Forensic Medicine (4.7k citations), Hematology (1.4k citations), Immunology (1.9k citations) and Oncology (2.1k citations). Stephen Opat has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Constantine Si Lun Tam, John Francis Seymour, Jake Shortt, Judith Trotman, Marek Trněný, Elizabeth H. Phillips, Günter Fingerle‐Rowson, Rudolf Schlag, Michael J. Herold and Robert E Marcus. Their work appears in journals such as Blood, Hematological Oncology, Blood Advances, HemaSphere and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.